Skip to main content

Table 1 Association between hepatoblastoma risk and polymorphisms in NRAS and KRAS

From: NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children

Genotype Patients (n = 213) Controls (n = 958) P a Crude OR (95% CI) P Adjusted OR (95% CI)b P b
NRAS rs2273267 A > T (HWE = 0.794)
 AA 103 (48.36) 486 (50.73)   1.00   1.00  
 AT 88 (41.31) 395 (41.23)   1.05 (0.77–1.44) 0.755 1.05 (0.77–1.44) 0.758
 TT 22 (10.33) 77 (8.04)   1.35 (0.80–2.27) 0.259 1.35 (0.80–2.27) 0.259
 Additive    0.528 1.12 (0.89–1.40) 0.338 1.12 (0.89–1.40) 0.338
 Dominant 110 (51.64) 472 (49.27) 0.531 1.10 (0.82–1.48) 0.531 1.10 (0.82–1.48) 0.532
 Recessive 191 (89.67) 881 (91.96) 0.277 1.32 (0.80–2.17) 0.278 1.32 (0.80–2.17) 0.277
KRAS rs12587 G > T (HWE = 0.132)
 GG 128 (60.09) 609 (63.57)   1.00   1.00  
 GT 79 (37.09) 300 (31.32)   1.25 (0.92–1.71) 0.158 1.26 (0.92–1.72) 0.155
 TT 6 (2.82) 49 (5.11)   0.58 (0.24–1.39) 0.223 0.58 (0.24–1.39) 0.223
 Additive    0.130 1.04 (0.80–1.34) 0.789 1.04 (0.80–1.34) 0.788
 Dominant 85 (39.91) 349 (36.43) 0.342 1.16 (0.86–1.57) 0.342 1.16 (0.86–1.57) 0.341
 Recessive 207 (97.18) 909 (94.89) 0.152 0.54 (0.23–1.27) 0.158 0.54 (0.23–1.27) 0.158
KRAS rs7973450 A > G (HWE = 0.213)
 AA 178 (83.57) 798 (83.30)   1.00   1.00  
 AG 35 (16.43) 156 (16.28)   1.01 (0.67–1.50) 0.977 1.01 (0.67–1.50) 0.979
 GG 0 (0.00) 4 (0.42)   / / / /
 Additive    0.640 0.95 (0.65–1.41) 0.814 0.95 (0.65–1.41) 0.811
 Dominant 35 (16.43) 160 (16.70) 0.924 0.98 (0.66–1.46) 0.924 0.98 (0.66–1.46) 0.921
 Recessive 213 (100.00) 954 (99.58) 0.345 / / / /
KRAS rs7312175 G > A (HWE = 0.300)
 GG 167 (78.40) 740 (77.24)   1.00   1.00  
 GA 44 (20.66) 200 (20.88)   0.98 (0.68–1.41) 0.892 0.98 (0.68–1.41) 0.892
 AA 2 (0.94) 18 (1.88)   0.49 (0.11–2.14) 0.345 0.49 (0.11–2.15) 0.345
 Additive    0.626 0.91 (0.65–1.26) 0.553 0.91 (0.65–1.26) 0.554
 Dominant 46 (21.60) 218 (22.76) 0.714 0.94 (0.65–1.34) 0.714 0.94 (0.65–1.34) 0.715
 Recessive 211 (99.06) 940 (98.12) 0.338 0.50 (0.11–2.15) 0.348 0.50 (0.11–2.15) 0.348
Combined effect of protective genotypesc
 0 139 (65.26) 605 (63.15)   1.00   1.00  
 1 63 (29.58) 303 (31.63)   0.91 (0.65–1.26) 0.551 0.91 (0.65–1.26) 0.552
 2 9 (4.23) 26 (2.71)   1.51 (0.69–3.29) 0.303 1.51 (0.69–3.29) 0.302
 3 2 (0.94) 24 (2.51)   0.36 (0.09–1.55) 0.172 0.36 (0.09–1.55) 0.172
Trend    0.306 0.92 (0.73–1.16) 0.458 0.92 (0.73–1.16) 0.458
 0 139 (65.26) 605 (63.15)   1.00   1.00  
 1–3 74 (34.74) 353 (36.85) 0.564 0.91 (0.67–1.25) 0.564 0.91 (0.67–1.25) 0.561
  1. OR odds ratio, CI confidence interval, HWE Hardy–Weinberg equilibrium
  2. aBy χ2 test vs. cancer-free controls
  3. bAdjusted for age and gender
  4. cRisk genotypes are rs12587 TT, rs7973450 AG/GG, and rs7312175 GA/AA
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us